None listed
Conditions
Brief summary
The objective of the clinical trial is to demonstrate that monitoring of weight improves the compliance rate of CHF patient’s to self-monitor their daily weight, as well as potentially improved quality of life, enhanced management of risk factors and medication, increased cost benefits and reduced hospital readmissions.
Interventions
Patients who consent to participate in the trial will be randomised to one of two groups: (a) Usual Care Group (b) Enhanced Care Group (a) Usual Care Group Participants in the Usual Care Group will receive the usual standard-of-care as provided by their GP and Cardiologists. Usual care advice and treatment for people with CHF typically involves patient education (eg, importance of daily weight monitoring, fluid restriction monitoring), daily monitoring of body weight, and visits to their GP or other health care providers according to their self-assessment. As per the usual standard-of-care, patients in the Usual Care Group will be required to monitor their weight on a daily basis and record their weight measurements in a weight diary. The study team will provide the Usual Care Group with an electronic weight scale with memory for self-monitoring. The data gathered in the weight scale will be stored in the scale’s memory and extracted at regular intervals by the research team over a 12 month period. (b) Enhanced Care Group Participants in the Enhanced Care Group will receive a revised model of the usual standard care for chronic heart failure patients as provided by their GP and Cardiologist. As per the usual standard-of-care, patients in the Enhanced Care Group will be required to monitor their weight on a daily basis. The Enhanced Care Group will be provided with an electronic weight scale (with memory); however the weight measurements will be recorded in real time via remote monitoring over a 12 month period. Participants in the both groups will also complete a series of assessments at baseline, 6-months and 12-months which will involve: * Collection of demographic details * Previous clinical history * Risk factor assessment * Quality of life assessment * Functional or physical capacity * Health behaviours * Medication management * Symptoms * Participant usability evaluation questionnaire (at 12 months only)
Sponsors
Study design
Eligibility
Inclusion criteria
Eligible participants will be patients diagnosed with chronic heart failure. Inclusion criteria are that the participants must: 1. Diagnosed as having chronic heart failure by a clinician 2. Be able to weigh themselves safely 3. At least 18 years of age 4. Have regular GP/agree to use GP designated by the patient 5. Have permanent residential address 6. Able to individually consent
Exclusion criteria
Patients will not be eligible for participation in the project if they 1. Have life expectancy less than12 months 2. Have end stage renal failure on dialysis 3. Are long term nursing home resident 4. Have severe cognitive impairment